KRAS mutation is the most common genetic event in pancreatic cancer. Whereas KRAS itself has proven difficult to inhibit, agents that target key downstream signals of KRAS, such as RAF, are possibly effective for pancreatic cancer treatment. Because selective BRAF inhibitors paradoxically induce downstream signaling activation, a pan-RAF inhibitor, LY3009120 is a better alternate for KRAS-mutant tumor treatment. Here we explored a new combinational strategy using a YAP inhibitor and LY3009120 in pancreatic cancer treatment.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rCEx6J
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Abstract Bone homeostasis is maintained by a balance between resorption of the bone matrix and its replacement by new bone. Osteoclasts p...
-
Abstract Continuous tooth replacement is common for tetrapods, but some groups of acrodont lepidosaurs have lost the ability to replace th...
-
ACS Nano DOI: 10.1021/acsnano.6b07537 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2i580k9 via...
-
Abstract Background Histamine intolerance is thought to trigger manifold clinical symptoms after ingesting histamine-rich food due to re...
-
Editorial introductions No abstract available Editorial: COVID-19 in older persons: the role of nutrition No abstract available A year with ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου